Compare Abeona Therapeutics Inc (ABEO) vs Realty Income Corp (O) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Realty Income Corp — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Realty Income Corp trades at $63.43 (market cap $59.69B). The key difference: Realty Income Corp is far larger — about 159.9× Abeona Therapeutics Inc's market cap, and Realty Income Corp pays a 5.08% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | O | |
|---|---|---|
Market Cap | $373.32M | $59.69B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $67.56 |
52-Week Low | $4.17 | $55.93 |
Enterprise Value | $228.22M | $89.49B |
Dividend Yield | — | 5.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Realty Income (O) trades at $64.01, up 0.27% with a bullish technical signal from moving averages. The REIT maintains strong fundamentals with $5.75B revenue (2025), 92.54% gross margins, and consistent monthly dividends. Recent earnings missed expectations for three consecutive quarters, but analyst consensus remains positive with a $67.86 price target. Operating cash flow grew to $4.0B in 2025, though debt-to-asset ratio increased to 39.93%.
Outlook remains stable with dividend reliability as a key strength, but elevated P/E (51.8) and recent earnings misses pose valuation concerns. Risks include rising leverage and interest rate sensitivity. Institutional sentiment leans bullish (41% buy ratings), supporting moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
